|
|
| Line 1: |
Line 1: |
| | #REDIRECT [[Tenecteplase#Warnings]] |
|
| |
|
| __NOTOC__
| | [[Category: Cardiovascular Drugs]] |
| {{Tenecteplase}}
| | [[Category: Drug]] |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Warnings And Precautions==
| |
| ===WARNINGS===
| |
| | |
| ====Bleeding====
| |
| | |
| The most common complication encountered during TNKase therapy is bleeding. The type of bleeding associated with thrombolytic therapy can be divided into two broad categories:
| |
| | |
| *Internal bleeding, involving intracranial and retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts.
| |
| *Superficial or surface bleeding, observed mainly at vascular puncture and access sites (e.g., venous cutdowns, arterial punctures) or sites of recent surgical intervention.
| |
| | |
| Should serious bleeding (not controlled by local pressure) occur, any concomitant [[heparin]] or antiplatelet agents should be discontinued immediately.
| |
| | |
| In clinical studies of TNKase, patients were treated with both aspirin and [[heparin]]. [[heparin]] may contribute to the bleeding risks associated with TNKase. The safety of the use of TNKase with other antiplatelet agents has not been adequately studied (see PRECAUTIONS: Drug Interactions). Intramuscular injections and nonessential handling of the patient should be avoided for the first few hours following treatment with TNKase. Venipunctures should be performed and monitored carefully.
| |
| | |
| Should an arterial puncture be necessary during the first few hours following TNKase therapy, it is preferable to use an upper extremity vessel that is accessible to manual compression. Pressure should be applied for at least 30 minutes, a pressure dressing applied, and the puncture site checked frequently for evidence of bleeding.
| |
| | |
| Each patient being considered for therapy with TNKase should be carefully evaluated and anticipated benefits weighed against potential risks associated with therapy. In the following conditions, the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits:
| |
| | |
| *Recent major surgery, e.g., [[coronary artery bypass graft]], obstetrical delivery, organ biopsy, previous puncture of noncompressible vessels
| |
| *Cerebrovascular disease
| |
| *Recent gastrointestinal or genitourinary bleeding
| |
| *Recent trauma
| |
| *[[hypertension]]: systolic BP ≥180 mm Hg and/or diastolic BP ≥110 mm Hg
| |
| *High likelihood of left heart thrombus, e.g., mitral stenosis with [[atrial fibrillation]]
| |
| *Acute [[pericarditis]]
| |
| *[[Subacute bacterial endocarditis]]
| |
| *Hemostatic defects, including those secondary to severe hepatic or renal disease
| |
| *Severe [[hepatic dysfunction]]
| |
| *Pregnancy
| |
| *Diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions
| |
| *Septic thrombophlebitis or occluded AV cannula at seriously infected site
| |
| *Advanced age (see PRECAUTIONS: Geriatric Use)
| |
| *Patients currently receiving oral anticoagulants, e.g., warfarin sodium
| |
| *Recent administration of GP IIb/IIIa inhibitors
| |
| *Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location
| |
| | |
| ====Cholesterol Embolization====
| |
| | |
| [[Cholesterol embolism]] has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown. This serious condition, which can be lethal, is also associated with invasive vascular procedures (e.g., cardiac [[catheterization]], [[angiography]], vascular surgery) and/or anticoagulant therapy. Clinical features of [[cholesterol embolism]] may include livedo [[reticularis]], "purple toe" syndrome, [[acute renal failure]], gangrenous digits, [[hypertension]], [[pancreatitis]], [[[[myocardial infarction]]]], [[cerebral infarction]], spinal cord infarction, retinal artery occlusion, bowel infarction, and rhabdomyolysis.
| |
| | |
| ====[[Arrhythmias]]====
| |
| | |
| Coronary thrombolysis may result in arrhythmias associated with [[reperfusion]]. These [[arrhythmias]] (such as [[sinus bradycardia]], accelerated idioventricular rhythm, ventricular premature depolarizations, [[ventricular tachycardia]]) are not different from those often seen in the ordinary course of acute [[myocardial infarction]] and may be managed with standard anti‑arrhythmic measures. It is recommended that anti‑arrhythmic therapy for [[bradycardia]] and/or ventricular irritability be available when TNKase is administered.
| |
| | |
| Use with [[Percutaneous Coronary Intervention]] ([[PCI]])
| |
| | |
| In patients with large ST segment elevation [[myocardial infarction]], physicians should choose either thrombolysis or [[PCI]] as the primary treatment strategy for [[reperfusion]]. Rescue [[PCI]] or subsequent elective [[PCI]] may be performed after administration of thrombolytic therapies if medically appropriate; however, the optimal use of adjunctive antithrombotic and antiplatelet therapies in this setting is unknown.
| |
| | |
| ===PRECAUTIONS===
| |
| | |
| ====General====
| |
| | |
| Standard management of [[myocardial infarction]] should be implemented concomitantly with TNKase treatment. Arterial and venous punctures should be minimized. Noncompressible arterial puncture must be avoided and internal jugular and subclavian venous punctures should be avoided to minimize bleeding from the noncompressible sites. In the event of serious bleeding, [[heparin]] and antiplatelet agents should be discontinued immediately. [[heparin]] effects can be reversed by protamine.
| |
| | |
| ====Readministration====
| |
| | |
| Readministration of plasminogen activators, including TNKase, to patients who have received prior plasminogen activator therapy has not been systematically studied. Three of 487 patients tested for antibody formation to TNKase had a positive antibody titer at 30 days. The data reflect the percentage of patients whose test results were considered positive for antibodies to TNKase in a radioimmunoprecipitation assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including sample handling, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to TNKase with the incidence of antibodies to other products may be misleading. Although sustained antibody formation in patients receiving one dose of TNKase has not been documented, readministration should be undertaken with caution. If an anaphylactic reaction occurs, appropriate therapy should be administered.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TNKASE (TENECTEPLASE) KIT [GENENTECH, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69e391bf-1250-4083-aa60-6aa41c33657f | publisher = | date = | accessdate = 6 February 2014 }}</ref>
| |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Thrombolytic drugs]]
| |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Drugs]] | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |